Search for Clinical Trial Results

Status	Study
Recruiting	Study Name: Olaparib and Cediranib Maleate in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Condition: Deleterious BRCA1 Gene Mutation Deleterious BRCA2 Gene Mutation Drug: Cediranib Maleate Given